Lineage Cell Therapeutics shares rise 1.49% intraday after beating Wall Street earnings expectations.

Lineage Cell Therapeutics, Inc. rose 1.49% in intraday trading, with the company reporting a loss of $30.5 million in its second quarter, which beat Wall Street expectations. The biotechnology company posted revenue of $2.8 million in the period, also surpassing Street forecasts.